TITLE

Emtricitabini ettenofoviri compressi: Emtricitabine and tenofovir tablets

PUB. DATE
December 2010
SOURCE
WHO Drug Information;2010, Vol. 24 Issue 4, p330
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on several chemical tests that the World Health Organization conducted in 2010 on the combination antiretroviral treatment which features the drugs Emtricitabine and tenofovir to evaluate the drugs' safety and efficacy. A discussion of recommendations which the organizations offered for the proper strength and storage of the drugs is presented.
ACCESSION #
60174658

 

Related Articles

  • BTL Editorial: An Epidemic Solution After 30 Years Should Be Embraced.  // Between the Lines (10807551);5/22/2014, Issue 2221, p5 

    The article offers information on Truvada, a new drug being used in the HIV prevention technology Pre-Exposure Prophylaxis (PrEP).

  • Efavirenz/emtricitabine/tenofovir disoproxil fumarate.  // Reactions Weekly;1/12/2013, Issue 1434, p25 

    The article presents a case study of a 38-year-old man who, while receiving efavirenz/emtricitabine/tenofovir disoproxil fumarate, developed psychosis.

  • ARC Ohio Begins Clinics for HIV-Prevention Drug.  // Outlook Ohio Magazine;Oct2014, Vol. 19 Issue 5, p14 

    The article reports that non-profit organization AIDS Resource Center in Columbus, Ohio has started taking appointments in September 2014 from HIV-negative adults interested in pre-exposure prophylaxis (PrEP), which includes a daily dose of Truvada drug to reduce the risk of HIV infection.

  • Efavirenz/lamivudine/stavudine.  // Reactions Weekly;11/20/2010, Issue 1328, p18 

    The article describes the case of a boy with HIV infection who developed paradoxical immune reconstitution inflammatory syndrome (IRIS) with chylous ascites and chylothorax during Highly Active Antiretroviral Therapy (HAART) with stavudine, efavirenz and lemivudine.

  • Final data confirm PrEP reduced risk for HIV in heterosexual couples. Henry, Jennifer; Shafer, Emily // Infectious Disease News;Apr2012, Vol. 25 Issue 4, p17 

    The article reports on the findings by researchers from the University of Washington that once-daily tenofovir and combination emtricitabine/tenofovir reduced the risk for HIV infection in heterosexual men and women with a partner who is HIV-positive.

  • Emtricitabine/Tenofovir (Truvada) for HIV Prophylaxis. COUTINHO, BARRY; PRASAD, RAMAKRISHNA // American Family Physician;10/15/2013, Vol. 88 Issue 8, p539 

    This article presents information on emtricitabine/tenofovir, a fixed-dose combination of emtricitabine and tenofovir that was labeled for use as preexposure prophylaxis to prevent HIV-1 infection.

  • Efavirenz/rifabutin interaction.  // Reactions Weekly;7/2/2011, Issue 1358, p16 

    The article describes the case of a 42-year-old man who developed decreased efavirenz concentrations due to interaction with rifabutin and efavirenz, published in the October 2010 issue of the "American Journal of Health-System Pharmacy."

  • Efavirenz, emtricitabine and tenofovir tablets.  // WHO Drug Information;2010, Vol. 24 Issue 4, p323 

    The article reports on several chemical tests which the World Health Organization conducted on the combination antiretroviral treatment that contains the drugs Efavirenz, emtricitabine and tenofovir to determine the safety and efficacy of the drugs. A discussion of recommendations which the...

  • Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial. Lortholary, Olivier; Roussillon, Caroline; Boucherie, Céline; Padoin, Christophe; Chaix, Marie-Laure; Breton, Guillaume; Rami, Agathe; Veziris, Nicolas; Patey, Olivier; Caumes, Eric; May, Thierry; Molina, Jean-Michel; Robert, Jérome; Tod, Michel; Fagard, Catherine; Chêne, Geneviève; ANRS 129 BKVIR Trial Group // Journal of Antimicrobial Chemotherapy (JAC);Mar2016, Vol. 71 Issue 3, p783 

    Background: HIV-infected patients with TB need simplified, effective and well-tolerated antiretroviral regimens.Methods: The French ANRS 129 BKVIR open trial evaluated the once-daily tenofovir DF/emtricitabine and efavirenz combination, started within 12 weeks after TB...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics